Program - Society of Toxicology

More documents

Recommendations

Info

50 th Anniversary Annual Meeting and ToxExpo Program Description (Continued) MONday Abstract # Abstract # #780 Poster Board Number.....................................906 QUANTIFIED TRACKING AND MONITORING OF DIAZEPAM TREATED SOCIALLY HOUSED CYNOMOLGUS MONKEYS. C. Rose 1 , J. E. van der Harst 2 , R. C. de Heer 2 , B. M. Spruijt 2 and S. H. Korte 1 . 1 Covance Laboratories GmbH, Muenster, Germany and 2 Delta Phenomics BV, Utrecht, Netherlands. Sponsor: G. Weinbauer. #781 Poster Board Number.....................................907 28-DAY TOXICITY STUDY WITH THE NON- TRADITIONAL VEHICLE SOLUTOL HS15 AND POLYETHYLENE GLYCOL 400 IN FEMALE BEAGLE DOGS. D. Kemp, J. Hailey, H. Jordan, R. Brown and D. Bailey. GlaxoSmithKline, Research Triangle Park, NC. #782 Poster Board Number.....................................908 TOXICITY OF MDL72, 527 ADMINISTERED ORALLY TO RATS AND DOGS. S. D. Grimes 1 , R. W. Watkins 1 , J. F. Mann 1 , H. S. Basu 2 , I. M. Kapetanovic 3 and C. D. Hebert 1 . 1 Southern Research Institute, Birmingham, AL, 2 Colby Pharmaceutical Company, Menlo Park, CA and 3 National Cancer Institute, Bethesda, MD. #783 Poster Board Number.....................................909 SAFETY ASSESSMENT OF PHOSPHO- IBUPROFEN AS A POTENTIAL CANCER CHEMOPREVENTIVE AGENT. R. W. Watkins 1 , J. F. Mann 1 , S. D. Grimes 1 , R. Fulton 2 , C. V. Rao 3 , I. M. Kapetanovic 4 and C. D. Hebert 1 . 1 Southern Research Institute, Birmingham, AL, 2 FVClinPath Consulting, Birmingham, AL, 3 University of Oklahoma Health Sciences Center, Oklahoma City, OK and 4 National Cancer Institute, Bethesda, MD. #784 Poster Board Number.....................................910 EARLY SAFETY ASSESSMENT CONSIDERATIONS AND STRATEGIES IN DRUG DISCOVERY. S. Mohr 1 , A. J. Olaharski 2 , F. Crameri 1 , T. Singer 1 and T. Weiser 1 . 1 Nonclinical Safety, F. Hoffmann-La Roche, Basel, Switzerland and 2 Nonclinical Safety, F. Hoffmann-La Roche, Nutley, NJ. #785 Poster Board Number.....................................911 ASSESSMENT OF HEMATOLOGICAL TOXICITY ASSOCIATED WITH COMBINING CLASSICAL CHEMOTHERAPEUTIC AND TARGETED CANCER DRUGS. S. Khoh-Reiter, D. Lee and B. Jessen. Pfizer Inc., San Diego, CA. #786 Poster Board Number.....................................912 HUMAN NON-RELEVANCE OF MOTILIN AGONIST INDUCED ANAPHYLACTOID REACTIONS IN BEAGLE DOGS. P. Chowdhury and C. Powell. Safety Assessment, GlaxoSmithKline, Ware, United Kingdom. #787 Poster Board Number.....................................913 AN IMPROVED ORAL TOXICITY PROFILE OF A NOVEL BOTULINUM TOXIN TYPE A FORMULATION. H. F. Stone, T. D. Thach, L. Garcia and C. L. Ruegg. Revance Therapeutics, Newark, CA. #788 Poster Board Number.....................................914 NONCLINICAL TOXICOLOGY OF BIIB022, AN ANTI-IGF-1R MONOCLONAL ANTIBODY. K. Stickland 1 , E. Polack 1 , J. Galluppi 1 , J. Morrow 1 , J. Clarke 1 , S. Chuang 2 , S. Tichenor 2 , L. Huard 3 and S. Rose 2 . 1 Biogen Idec, Cambridge, MA, 2 Charles River Laboratories, Reno, NV and 3 Charles River Laboratories, Montréal, QC, Canada. #789 Poster Board Number.....................................915 PPD10558: AN ORALLY EFFECTIVE STATIN WITHOUT MYOTOXIC EFFECTS. R. A. Lopez 1 , D. Prohaska 1 , G. McIntyre 1 and M. Griggs 2 . 1 Furiex Pharmaceuticals, Inc., Morrisville, NC and 2 MPI Research, Mattawan, MI. #790 Poster Board Number.....................................916 COMPREHENSIVE INVESTIGATION OF PROPYLENE GYLCOL, POLYSORBATE 80, AND HYDROXYPROPYL-BETA- CYCLODEXTRIN FOR USE IN GENERAL, REPRODUCTIVE, AND DEVELOPMENTAL TOXICOLOGY STUDIES. E. A. Thackaberry 1 , S. Kopytek 2 , P. Sherratt 3 , K. Trouba 4 , B. McIntyre 5 , K. A. Treinen 2 and B. P. Enright 6 . 1 Safety Assessment, Genentech, South San Francisco, CA, 2 Safety Assessment, Merck Research Laboratories, Summit, NJ, 3 Toxicology, Celgene Corporation, Summit, NJ, 4 Drug Safety Evaluation, Bristol-Myers Squibb, Mt. Vernon, IN, 5 National Toxicology Program, National Institute of Environmental Health Science, Research Triangle Park, NC and 6 Preclinical Safety, Abbott Laboratories, Abbott Park, IL. #791 Poster Board Number.....................................917 NONCLINICAL DEVELOPMENT OF BMN 110, AN ENZYME REPLACEMENT THERAPY FOR MUCOPOLYSACCHARIDOSIS TYPE IVA (MPS IVA). F. Lorget, D. Kennedy, Y. Qi, L. Argento Martell, A. Van Tuyl, M. Dvorak-Ewell, E. Paysinger, C. O’Neill and L. Tsuruda. BioMarin Pharmaceuticals Inc., Novato, CA. #792 Poster Board Number.....................................918 GASTROINTESTINAL TOXICITY IN RATS FOLLOWING ORAL ADMINISTRATION OF AURORA KINASE INHIBITORS. M. J. Anderton 1 , H. Mellor 1 , J. Barnes 1 , T. Child 1 , N. Barrass 1 , P. Cotton 1 , S. Green 2 , J. Foster 1 and R. Roberts 1 . 1 Safety Assessment UK, AstraZeneca, Cheshire, United Kingdom and 2 Cancer Research Department, AstraZeneca, Cheshire, United Kingdom. #793 Poster Board Number.....................................919 HSP90 INHIBITORS REDUCE ELECTRORETINOGRAM RESPONSES IN DOGS. C. Somps 1 , C. Liu 1 , N. Poy 3 , J. Marcek 1 and V. Torti 2 . 1 Drug Safety R&D, Pfizer, Inc., Groton, CT, 2 Drug Safety R&D, Pfizer, Inc., La Jolla, CA and 3 World Wide Comparative Medicine, Pfizer, Inc., Groton, CT. #794 Poster Board Number.....................................920 SUBCHRONIC ORAL TOXICITY EVALUATION OF CP31398, A P53 STABILIZER, IN RATS. D. L. McCormick 1 , W. D. Johnson 1 , M. Muzzio 1 , C. J. Detrisac 2 , L. Kopelovich 3 and I. M. Kapetanovic 3 . 1 IIT Research Institute, Chicago, IL, 2 Pathology Associates, Chicago, IL and 3 National Cancer Institute, Bethesda, MD. 182 Education-Career Development Sessions Exhibitor Hosted Sessions Featured Sessions Historical Highlights Informational Sessions Platform Sessions
Society of Toxicology 2011 Program Description (Continued) Abstract # #795 Poster Board Number.....................................921 SUBCHRONIC ORAL TOXICITY EVALUATION OF CP31398, A P53 STABILIZER, IN DOGS. W. D. Johnson 1 , M. Muzzio 1 , C. J. Detrisac 2 , L. Kopelovich 3 , I. M. Kapetanovic 3 and D. L. McCormick 1 . 1 IIT Research Institute, Chicago, IL, 2 Pathology Associates, Chicago, IL and 3 National Cancer Institute, Bethesda, MD. #796 Poster Board Number.....................................922 SUBCUTANEOUS ADMINISTRATION STUDY TO DETERMINE THE INFLUENCE OF AN ANTI-MOUSE IL-12/IL-23P40 ANTIBODY ON PHOTOCARCINOGENESIS IN HAIRLESS MICE. W. M. Bracken 1 , D. Learn 2 , G. Blaich 1 and G. M. Veldman 3 . 1 Global Preclinical Safety, Abbott, Abbott Park, IL, 2 Photobiology, CRL, Horsham, PA and 3 Biologics Generation, Abbott Bioresearch Center, Worcester, MA. #797 Poster Board Number.....................................923 ANTIBODY-MEDIATED VASCULITIS: IN VIVO INVESTIGATIONS INTO THE MECHANISM OF TOXICITY. K. Mackay 1 , T. Sullivan 1 , M. Carioto1, J. Senn 1 , J. Lane 2 , J. S. Michaelson 3 and J. C. Clarke 1 . 1 Pharmacotoxicology, Biogen Idec, Cambridge, MA, 2 Comparative Pathology, Biogen Idec, Cambridge, MA and 3 Immunobiology, Biogen Idec, Cambridge, MA. #798 Poster Board Number.....................................924 INHIBITION OF THE ENZYME S-NITROSOGLUTATHIONE (GSNO) REDUCTASE DOES NOT CAUSE MECHANISM-BASED TOXICITY. D. B. Colagiovanni, X. Sun, J. Qiu, A. Stout, A. Patton, L. Green, J. Richards and G. J. Rosenthal. Research, N30 Pharmaceuticals, Boulder, CO. #799 Poster Board Number.....................................925 ORAL TWO WEEK (3X/WEEK) DOSE RANGE FINDING STUDY OF DECITABINE AND TETRAHYDROURIDINE IN CD-1 MICE. K. Engelke 1 , E. Hanan 1 , J. Covey 2 , Y. Ling 3 , K. Chan 3 , Y. Saunthararajah 4 and P. Terse 2 . 1 AVANZA Laboratories, LLC, Gaithersburg, MD, 2 National Cancer Institute, Bethesda, MD, 3 Ohio State University, Columbus, OH and 4 Cleveland Clinic, Cleveland, OH. #800 Poster Board Number.....................................926 CONSEQUENCES OF REPEATED COMPLEMENT ACTIVATION AFTER CHRONIC TREATMENT IN CYNOMOLGUS MONKEYS. L. Shen 1 , T. Machemer 1 , P. Giclas 2 and S. Henry 1 . 1 ISIS Pharmaceuticals, Inc., Carlsbad, CA and 2 National Jewish Health, Denver, CO. #801 Poster Board Number.....................................927 SINGLE INTRACEREBROVENTRICULAR INFUSION TOXICITY, TOXICOKINETICS, AND DISTRIBUTION STUDY OF TRIPEPTIDYL PEPTIDASE-1 IN CYNOMOLGUS MONKEYS. B. Vuillemenot 1 , L. Tsuruda 1 , D. Kennedy 1 , D. Musson 1 , S. Keve 1 , R. Reed 2 , R. Boyd 2 , M. Butt 3 and C. O’Neill 1 . 1 BioMarin Pharmaceutical Inc., Novato, CA, 2 Northern Biomedical Research, Inc., Muskegon, MI and 3 ToxPath Specialists, LLC, Hagerstown, MD. Abstract # #802 Poster Board Number.....................................928 THE SAFETY OF CBD IN SOCIAL ANXIETY DISORDER PATIENTS. M. M. Bergamaschi 1,2 , M. Chagas 2 , D. Oliveira 2 , B. Martinis 3 , J. Hallak 2 , A. Zuardi 2 , J. Crippa 2 and R. Queiroz 1 . 1 School of Pharmaceutical Science of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil, 2 School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil and 3 School of Philosophy, Science and Literature of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil. #803 Poster Board Number.....................................929 IN VITRO MABEL APPROACH FOR NONCLINICAL SAFETY ASSESSMENT OF MEDI-565 (MT111), A NOVEL CEA/ CD3-BISPECIFIC SINGLE-CHAIN BITE ANTIBODY. P. C. Ryan 1 , S. A. Hammond 1 , S. Ren 1 , P. Lutterbuese 2 , M. Amann 2 , M. D. Oberst 1 , K. Mulgrew 1 , R. Criste 1 , S. Fuhrmann 1 , N. Lee 1 , R. Gross 1 , M. Liang 1 , A. Schneider 1 , R. Dixit 1 , P. A. Baeuerle 2 , B. Rattel 2 , S. Coats 1 , L. Roskos 1 , K. Bosslet 1 , B. Jallal 1 and L. Richman 1 . 1 MedImmune, Gaithersburg, MD and 2 Micromet, Bethesda, MD. #804 Poster Board Number.....................................930 HEAT SHOCK PROTEIN 90 INHIBITORS CAN INDUCE VISUAL CHANGES AND RETINAL DEGENERATION INCLUDING IRREVERSIBLE PHOTORECEPTOR LOSS IN DOGS. V. Torti 1 , J. Marcek 3 , K. Muravnick 3 , S. Aguirre 1 , J. Fortner 3 , J. Render 3 , T. Schmahai 3 , S. Yamazaki 2 , L. Nguyen 2 , Z. Shen 2 and L. Burns- Naas 1 . 1 DSRD, Pfizer Inc., La Jolla, CA, 2 PDM, Pfizer Inc., La Jolla, CA and 3 DSRD, Pfizer Inc., Groton, CT. #805 Poster Board Number.....................................931 BIOEQUIVALENCY OF TWO DIFFERENT METHOTREXATE FORMULATIONS IN HEPATIC GENE EXPRESSION OF PXB- MOUSE ® WITH HIGHLY HUMANIZED LIVER. M. Nakashima 1 , H. Tachiki 2 , T. Shimada 3 , D. Hynes 4 and S. Nagatsuka 4 . 1 Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan, 2 Research & Development Division, Towa Pharmaceutical Co., Ltd., Kadoma, Osaka, Japan, 3 PhoenixBio Co., Higashi-Hiroshima, Hiroshima, Japan and 4 R&D, Sekisui Medical Co., ADME & Toxicology Research Institute, Tokai-mura, Ibaraki, Japan. Sponsor: T. Miyaoka. #806 Poster Board Number.....................................932 PRECLINICAL ASPECTS OF BIOSIMILAR DEVELOPMENT – PRACTICAL CONSIDERATIONS. P. Baldrick and R. Donninger. Covance Laboratories Ltd., Harrogate, United Kingdom. Sponsor: S. Kirk. #807 Poster Board Number.....................................933 THE INCIDENCE OF TOXICOKINETIC CONTROL SAMPLE CONTAMINATION IN REGULATORY TOXICOLOGY STUDIES. S. Cahill and R. Turcan. Covance Laboratories Ltd., Harrogate, United Kingdom. Sponsor: S. Kirk. MONday Poster Sessions Regional Interest Session Roundtable Sessions Symposium Sessions Thematic Sessions Workshop Sessions 183
Page 1 and 2:
50 th Anniversary Annual Meeting &
Page 3 and 4:
Scientific Program Overview A page
Page 5 and 6:
9:00 AM-12:30 PM POSTER SESSionS
Page 7 and 8:
March 6-10, 2011 Walter E. Washingt
Page 9 and 10:
Celebration Activities Historical H
Page 11 and 12:
of the Society Regional Chapter Yea
Page 13 and 14:
SOT Presidents 1961-2011 1966 1967
Page 15 and 16:
The SOT Council Thanks and Recogniz
Page 17 and 18:
of the Past 50 Years 2003 Michael D
Page 19 and 20:
Thank You to the following individu
Page 21 and 22:
SOT Celebration Event Floor Plan Ba
Page 23 and 24:
50 th Anniversary Annual Meeting an
Page 25 and 26:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 27 and 28:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 29 and 30:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 31 and 32:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 33 and 34:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 35 and 36:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 37 and 38:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 39 and 40:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 41 and 42:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 43 and 44:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 45 and 46:
Toxicological Sciences The Official
Page 47 and 48:
Society of Toxicology 2011 Walter E
Page 49 and 50:
Society of Toxicology 2011 Washingt
Page 51 and 52:
Society of Toxicology 2011 Map of W
Page 53 and 54:
2011 SOT 50 th Anniversary Featured
Page 55 and 56:
Society of Toxicology 2011 Washingt
Page 57 and 58:
Society of Toxicology 2011 ToxExpo
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Society of Toxicology 2011 Exhibito
Page 65 and 66:
Creating a Safer and Healthier Worl
Page 67 and 68:
Society of Toxicology 2011 General
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
SOT Job Bank YOUR RECRUITMENT AND E
Page 83 and 84:
Society of Toxicology 2011 Career R
Page 85 and 86:
Society of Toxicology 2011 SOT 2011
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Society of Toxicology 2011 2011 Awa
Page 95 and 96:
Endowment Awardees for SOT’s 50 t
Page 97 and 98:
Society of Toxicology 2011 SOT Endo
Page 99 and 100:
Society of Toxicology 2011 Recognit
Page 101 and 102:
Society of Toxicology 2011 Recognit
Page 103 and 104:
Society of Toxicology 2011 RC, SIG,
Page 105 and 106:
Society of Toxicology 2011 Student
Page 107 and 108:
Society of Toxicology 2011 Outreach
Page 109 and 110:
Society of Toxicology 2011 Satellit
Page 111 and 112:
Society of Toxicology 2011 Continui
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Society of Toxicology 2011 Scientif
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Society of Toxicology 2011 Poster S
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Society of Toxicology 2011 Program
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154: Society of Toxicology 2011 Program
Page 203: Society of Toxicology 2011 Program
Page 255 and 256:
Page 257 and 258:
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
Page 265 and 266:
Page 267 and 268:
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
Page 305 and 306:
Page 307 and 308:
Page 309 and 310:
Page 311 and 312:
Page 313 and 314:
Page 315 and 316:
Page 317 and 318:
Page 319 and 320:
Page 321 and 322:
Page 323 and 324:
Page 325 and 326:
Page 327 and 328:
Page 329 and 330:
Page 331 and 332:
Page 333 and 334:
Page 335 and 336:
Page 337 and 338:
Page 339 and 340:
Page 341 and 342:
Page 343 and 344:
Page 345 and 346:
Page 347 and 348:
Page 349 and 350:
Page 351 and 352:
Page 353 and 354:
Page 355 and 356:
Page 357 and 358:
Page 359 and 360:
Page 361 and 362:
Page 363 and 364:
Page 365 and 366:
Page 367 and 368:
Page 369 and 370:
Page 371 and 372:
Page 373 and 374:
Page 375 and 376:
Page 377 and 378:
Page 379 and 380:
Page 381 and 382:
Society of Toxicology 2011 Author I
Page 383 and 384:
Page 385 and 386:
Page 387 and 388:
Page 389 and 390:
Page 391 and 392:
Page 393 and 394:
Page 395 and 396:
Page 397 and 398:
Page 399 and 400:
Page 401 and 402:
Page 403 and 404:
Page 405 and 406:
Page 407 and 408:
Page 409 and 410:
Society of Toxicology 2011 Abstract
Page 411 and 412:
Page 413 and 414:
Page 415 and 416:
Page 417 and 418:
Page 419 and 420:
Page 421 and 422:
Page 423 and 424:
Page 425 and 426:
Society of Toxicology 2011 2010-201
Page 427 and 428:
Society of Toxicology 2011 Elected
Page 429 and 430:
Society of Toxicology 2011 Elected
Page 431 and 432:
Society of Toxicology 2011 Regional
Page 433 and 434:
Society of Toxicology 2011 Specialt
Page 435 and 436:
Society of Toxicology 2011 Specialt
Page 437 and 438:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 439 and 440:
Society of Toxicology 2011 Endowmen
Page 441 and 442:
Page 443 and 444:
Page 445 and 446:
Page 447 and 448:
Society of Toxicology 2011 SOT Affi
Page 449 and 450:
Society of Toxicology 2011 Notes up
Page 451 and 452:
Society of Toxicology 2011 Notes up
Page 453 and 454:
Society of Toxicology 2011 Headquar
Page 455 and 456:
QUICK REFERENCE Visit www.mwata.com
show all

Program - Society of Toxicology

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?